Health
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
NEW YORK & NORTHBROOK, Ill., October 19, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/b012e61537a120567bbcfd030be1e12e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GKh9v55uj7c9sUOMERkY.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b012e61537a120567bbcfd030be1e12e","width":480,"height":212}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/51e435a7cd9fd37e9d7d2208457aa7c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EzPoCZQ7omg1j8myq1a0kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/51e435a7cd9fd37e9d7d2208457aa7c5","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/n.ta8sC_CPAXUVidVdDXEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/51e435a7cd9fd37e9d7d2208457aa7c5","width":1024,"height":512}}},{"type":"list","items":[{"val":[{"type":"text","content":"The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence1","length":223,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting","length":181,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Final results from the Phase 3 EMBARK study are being presented in a late-breaking oral session at ESMO 2025 and simultaneously published in The New England Journal of Medicine","length":176,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":580,"olType":false},{"type":"text","content":"NEW YORK & NORTHBROOK, Ill., October 19, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) r...